John Libbey Eurotext

European Journal of Dermatology

Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases Article à paraître

Illustrations

  • Figure 1
  • Figure 2

Tableaux

Auteurs
1 University François Rabelais,
Boulevard Tonnelé,
37044 Tours Cedex 9,
France
2 Department of Dermatology,
Hospital of Orléans,
1 rue Porte Madeleine,
45032 Orléans,
France
3 Department of Dermatology,
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
4 Department of Pathology,
Hospital of Tours,
Avenue de la République,
37044 Tours Cedex 9,
France
5 Department of Pathology,
Hospital of Orléans,
1 rue Porte Madeleine,
45032 Orléans,
France
6 International Agency for Research on Cancer,
Infections and Cancer Biology Group,
150 Cours Albert Thomas,
69372 Lyon CEDEX 08,
France
7 Laboratory “Biologie des Infections à Polyomavirus”,
ISP 1282,
INRA-University François,
Rabelais,
Tours,
France
* Reprints
  • Mots-clés : bullous pemphigoid, human herpes virus 8, kaposi sarcoma, methotrexate, topical steroids
  • DOI : 10.1684/ejd.2017.3027

Background

Iatrogenic Kaposi sarcoma (KS) has previously been reported in patients with bullous pemphigoid (BP), in relation to systemic steroids.